Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.81 |
| ▸ | SYK | P43405 | 11/20 | 0.72 |
| ▸ | CD63 | P08962 | 2/20 | 0.72 |
| ▸ | JAK2 | O60674 | 2/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.68 |
| ▸ | ROS1 | P08922 | 1/20 | 0.68 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.68 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.68 |
| ▸ | BTK | Q06187 | 1/20 | 0.68 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.68 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | YES1 | P07947 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2482275 | 0.95 | AURKA (0.79) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL2482747 | 0.91 | AURKA (0.77) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL24864097 | 0.89 | SYK (0.79) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL21471537 | 0.88 | AURKA (0.73) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL12017958 | 0.87 | AURKA (0.72) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL2481193 | 0.85 | AURKA (0.67) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL2481450 | 0.85 | AURKA (0.69) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL2479537 | 0.85 | AURKA (0.72) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL2476114 | 0.85 | SYK (0.70) | AURKASYKCD63JAK2NTRK1 | |
| SCHEMBL24179231 | 0.84 | AURKA (0.65) | AURKASYKCD63JAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002318-A1 | HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| US-11142535-B2 | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142535-B2 | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor | SYK, HDAC1, HDAC2 | AURKA 585/4885SYK 1/4885CD63 3229/4885 |
| US-20220002318-A1 | HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR | SYK, HDAC1, HDAC2 | AURKA 585/4885SYK 1/4885CD63 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.